Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. A diagnosis of hepatocellular carcinoma (HCC) based on either~   1. histopathologic or cytologic findings~  2. a diagnosis of cirrhosis and HCC with classical imaging characteristics (at least a 3-phase liver protocol CT or MRI and a lesion that demonstrates arterial enhancement and washes out in the venous phase)~2. Previous sorafenib treatment for at least 14 days and discontinuation of sorafenib treatment prior to inclusion~3. Radiologic confirmation of disease progression during or after discontinuation of sorafenib treatment or discontinuation of sorafenib due to intolerance despite appropriate supportive care~4. Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B disease not amenable to locoregional therapy or refractory to locoregional therapy~5. ≥ 1 measurable lesion according to RECIST Version 1.1~6. ≥ 20 year of age~7. ECOG performance status ≤ 2~8. Child-Pugh score ≤ 7~9. Informed consent prior to study~10. Adequate organ function~    1. Hepatic: bilirubin ≤ 1.5 times upper limit of institutional normal value (ULN), AST or ALT ≤ 5 x ULN~   2. Renal: estimated creatinine clearance ≥ 60 mL/min~   3. Hematologic: hemoglobin ≥ 9 g/dL, absolute neutrophil count (ANC) ≥ 1,500/μL, platelets ≥ 75,000/μL (In case of thrombocytopenia associated with hypersplenism in chronic liver disease, platelets ≥ 50,000/μL is allowed for participation at the physician's discretion.)~   4. Coagulation: prothrombin time (INR) ≤ 1.5, partial thrombin time (PTT) ≤ 5 seconds above the ULN~Exclusion Criteria:~1. Previous systemic chemotherapy for advanced disease (except previous biologic agents including VEGF inhibitors, TGF-beta inhibitors, or PD-1/PD-L1 blockers)~2. A history o f or current hepatic encephalopathy or clinically meaningful ascites~3. Grade 2 or more peripheral neuropathy~4. Prior liver transplant~5. History of any other cancer within 2 years (Patients with carcinoma in situ of any origin and patients with prior malignancy who are in remission and whose likelihood of recurrence is very low, may be eligible.)~6. A history of treatment with taxanes (paclitaxel or docetaxel)~7. Females who are pregnant or lactating~8. A know allergy or hypersensitivity reaction to any of the treatment components~9. Serious preexisting medical conditions that cannot adequately controlled with appropriate therapy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genexol-PM (Type: EXPERIMENTAL): Genexol-PM 100 mg/m2 intravenously for 1 hour on days 1, 8, and 15 of a 28-day cycle up to 8 cycles. Patients will receive study treatment until disease progression, unacceptable toxicity, or withdrawal of consent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues